Outside Publication

China Proposes Biotech Export Restrictions, Global Relay Intelligence & Practice

November 04, 2026

Partner Todd Liao and managing associate Mudan He co-authored an article for Global Relay Intelligence & Practice about China's proposed biotechnology export restrictions and their implications for multinational pharmaceutical companies, licensees, and acquirers.

The authors explain that the proposed rules would prohibit certain transfers of ownership of biotechnology platforms while preserving exceptions for licensing arrangements that do not transfer ownership. They note that companies should assess whether their agreements involve controlled technologies, distinguish product-specific licensing rights from underlying platform ownership, and review transaction structures, closing conditions, and technology-transfer obligations to manage regulatory and execution risks.

Read the full Global Relay Intelligence & Practice article >>
Subscription may be required.